Nuvalent, Inc.

Nuvalent, Inc. is a dynamic biotechnology research company focused on creating precisely targeted therapies for patients with cancer. Nuvalent is dedicated to overcoming the limitations of existing treatments for clinically proven kinase targets through innovative solutions. Leveraging deep expertise in structure-based design, Nuvalent develops small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.

Nuvalent, Inc. is committed to advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. The company’s primary address is One Broadway 14th Floor, Cambridge, Massachusetts 02142, US, where Nuvalent's dedicated team is working to transform cancer treatment.

Nuvalent, Inc. strives to improve patient outcomes through its groundbreaking research and development efforts. The company's focus on precision and innovation positions it as a leader in the biotechnology industry. We invite the management team at Nuvalent, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight your achievements and connect with a wider audience.